BioSyent In-Licenses Endocrinology Product for Canada
BioSyent In-Licenses Endocrinology Product for Canada
MISSISSAUGA, Ontario, June 12, 2024 (GLOBE NEWSWIRE) -- BioSyent Inc. ("BioSyent", "the Company", TSX Venture: RX) is pleased to announce that its wholly-owned subsidiary, BioSyent Pharma Inc. ("BioSyent Pharma"), has entered into an agreement with a European partner for an exclusive license to register, market, sell and distribute a new endocrinology product in Canada. BioSyent Pharma and its European partner have agreed to seek Health Canada approval of the product by the end of 2024.
2024年6月12日安大略省密西沙加（GLOBE NEWSWIRE）——BioSyent公司（“BioSyent”，“公司”，TSX Venture：RX）非常高興地宣佈，其全資子公司BioSyent Pharma Inc.（“BioSyent Pharma”）已與歐洲合作伙伴簽訂了一項獨家許可協議，在加拿大註冊、市場、銷售和分銷一種新的內分泌學產品。BioSyent Pharma與其歐洲合作伙伴已經同意在2024年底之前尋求加拿大衛生部的產品批准。
"We are excited to bring this innovative endocrinology product to Canadians while expanding and diversifying our product portfolio in a new therapeutic area," commented René Goehrum, President and CEO of BioSyent. "We see a significant opportunity with this product which will address an unmet medical need in Canada."
"我們很高興能夠將這種創新的內分泌學產品引入加拿大，同時擴大並多樣化我們在一個新的治療領域的產品組合，" BioSyent總裁兼首席執行官Rene Goehrum評論道："我們認爲這個產品有巨大的機會，將滿足加拿大未滿足的醫療需求。"
About BioSyent Inc.
關於BioSyent Inc.
Listed on the TSX Venture Exchange under the trading symbol "RX", BioSyent is a profitable growth-oriented specialty pharmaceutical company focused on in-licensing or acquiring innovative pharmaceutical and other healthcare products that have been successfully developed, are safe and effective, and have a proven track record of improving the lives of patients. BioSyent supports the healthcare professionals that treat these patients by marketing its products through its community, specialty and international business units.
BioSyent在TSX Venture Exchange上以交易符號“RX”上市，是一家盈利增長型專業藥品公司，專注於入股或收購已成功開發、安全有效、具有改善患者生活記錄的創新藥物和其他醫療保健產品。BioSyent通過其社區、專業和國際業務部門通過銷售其產品來支持治療這些患者的醫療人員。
As of the date of this press release, the Company has 11,584,305 common shares outstanding.
截至本新聞發佈日期，公司共有11,584,305股普通股在外流通。
For a direct market quote for the TSX Venture Exchange and other Company financial information please visit .
有關TSX Venture Exchange的直接市場報價和其他公司財務信息，請訪問.
For further information please contact:
Mr. René C. Goehrum
President and CEO
BioSyent Inc.
E-Mail: investors@biosyent.com
Phone: 905-206-0013
Web:
要了解更多信息，請聯繫：
Rene C. Goehrum先生
總裁和首席執行官
BioSyent公司
電子郵件：investors@biosyent.com
電話：905-206-0013
網站：
This press release may contain information or statements that are forward-looking. The contents herein represent our judgment, as at the release date, and are subject to risks and uncertainties that may cause actual results or outcomes to be materially different from the forward-looking information or statements. Potential risks may include, but are not limited to, those associated with clinical trials, product development, future revenue, operations, profitability and obtaining regulatory approvals.
本新聞稿可能包含前瞻性信息或聲明。這裏的內容代表我們的判斷，截至發佈日期，並受到風險和不確定性的影響，這些風險和不確定性可能導致實際結果或結果與前瞻性信息或聲明有實質性不同。潛在的風險可能包括但不限於臨床試驗、產品開發、未來收入、運營、盈利能力和獲得監管批准。
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
TSX創業板及其監管服務供應商（如TSX創業板的政策所定義）對本新聞稿的充分性或準確性不承擔任何責任。
譯文內容由第三人軟體翻譯。